MGMT and glioblastoma: Series of phase III clinical trials displayed disappointing results of PD⁃1 in glioblastoma, including the OS of recurrent glioblastoma in CheckMate-143, OS of newly diagnosed MGMT⁃unmethylated glioblastoma, PFS of newly diagnosed MGMT⁃methylated glioblastoma (49–51).